Recently, studies on PDE inhibitors have confirmed their antifibrotic potential in various animal models, such as renal and hepatic fibrosis, through the augmentation of tissue cAMP and/or cGMP levels, consequently inhibiting fibroblast/myofibroblast transformation, activation, and suppression of extracellular matrix deposition (8-10). This evidence concerns the gene ALDH7A1 and Hepatic fibrosis.